Abstract

Aim: Transcatheter arterial embolization (TAE) is increasingly used as second-line therapy for non-variceal gastrointestinal bleeding (NVGIB) when endoscopic hemostasis fails. This study investigated factors influencing rebleeding, mortality, and length of hospital stay (LOS) following TAE.
Materials and Methods: We retrospectively analyzed 50 patients (mean age 64.8 years; 72% male) who underwent TAE for acute NVGIB between April 2023 and April 2025. Demographic variables, comorbidities, laboratory values, endoscopic/angiographic findings, embolic materials, and outcomes were reviewed. Primary outcomes were rebleeding and in-hospital mortality; secondary outcomes were LOS and overall mortality.
Results: Technical success was 97.9%. Rebleeding occurred in 30% (15/50), predominantly within one week. Risk was higher with malignancy (45.5%), systemic disease/bleeding disorders (29.4%), multivessel embolization (66.7% vs 21.1%), and negative endoscopic findings (75% vs 25.6%) (all p

Key words: Transcatheter arterial embolization; gastrointestinal bleeding; non-variceal hemorrhage; rebleeding; mortality; prognostic factors.